Korro Bio Inc reports results for the quarter ended September 30 - Earnings Summary

Korro Bio

12/11/2024 23:15

* Korro Bio Inc  KRRO.OQ  reported a quarterly adjusted loss
of
$2.26​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-15.50.  The mean expectation of six analysts for the
quarter was for a loss of $2.61 per share. Wall Street expected
results to range from $-2.84 to $-2.40 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Korro Bio Inc's reported EPS for the quarter was a loss of
$2.26​.
    * The company reported a quarterly loss of $21 million.
    * Korro Bio Inc shares had risen by 119.9% this quarter and
gained 53.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Korro Bio Inc is
120.00 
This summary was machine generated from LSEG data November 12 at
11:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -2.61          -2.26          Beat
 Jun. 30 2024                     -2.43          
 Mar. 31 2024      -2.36          -2.44          Missed
 Dec. 31 2023      -2.36          -25.65         Missed